BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26409615)

  • 1. Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required.
    McKenna C; Soares M; Claxton K; Bojke L; Griffin S; Palmer S; Spackman E
    Value Health; 2015 Sep; 18(6):865-75. PubMed ID: 26409615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; Soares M; Spackman E; Rothery C
    Value Health; 2016; 19(6):885-891. PubMed ID: 27712718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
    Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
    Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.
    Gialama F; Miloni E; Maniadakis N
    Pharmacoeconomics; 2014 Nov; 32(11):1063-78. PubMed ID: 25082388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
    Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
    Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
    Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
    Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
    Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
    Kolm P; Yuan Y; Veledar E; Mehta SR; O'Brien JA; Weintraub WS
    Can J Cardiol; 2007 Nov; 23(13):1037-42. PubMed ID: 17985004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
    Janzon M; James S; Cannon CP; Storey RF; Mellström C; Nicolau JC; Wallentin L; Henriksson M
    Heart; 2015 Jan; 101(2):119-25. PubMed ID: 25227704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(5):1-70. PubMed ID: 23074496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of ticagrelor in acute coronary syndromes.
    Henriksson M; Janzon M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):9-18. PubMed ID: 23402441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
    Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.